Predict your next investment

BIOARRAY Genetics company logo
HEALTHCARE | Disease Diagnosis
bioarray.us

See what CB Insights has to offer

Founded Year

2009

Stage

Series B - II | Alive

Total Raised

$6.69M

Last Raised

$4M | 4 yrs ago

About BIOARRAY Genetics

BIOARRAY Genetics, fka BIOARRAY Therapeutics, is developing a chemotherapy response assay designed to help guide physicians in the selection of the most effective treatment, the first time. Specifically, the product is a quantitative in-vitro diagnostic test that uses a breast cancer patient's gene expression profile (RNA expression levels), along with proprietary algorithms, to assess the patient's likelihood of responding to each of several standard-of-care, pre-surgery, taxane-based chemotherapy options. Such a tool will provide physicians with critical information at the early stage of the care cycle and has the potential to improve clinical outcomes, reduce ineffective treatments, and save treatment costs.

BIOARRAY Genetics Headquarter Location

400 Farmington Avenue

Farmington, Connecticut, 06032,

United States

508-577-0205

Latest BIOARRAY Genetics News

14:30 ET Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Am...

Jul 5, 2021

News provided by Share this article Share this article Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever. Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall. This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 4.3.2 Bioinformatics Plays a Role 4.4 Diagnostic Technology Development 4.4.2 Single Cell Genomics Changes the Picture 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 4.4.4 CGES Testing, A Brave New World 4.4.5 Biochips/Giant magneto resistance based assay 5 Cancer Panels & Profiles Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Dante Labs Acquires Cambridge Cancer Genomics 5.3 Celemics, Strand Partner on Integrated Platform for NGS Analysis 5.4 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries 5.5 Burning Rock Revenues Rise 5.6 Caris Life Sciences to Expand Liquid Biopsy Testing 5.7 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence 5.8 Intermountain and Myriad Combine Test Offering 5.9 Illumina, Geneseeq to Offer Cancer Testing Kits in China 5.10 Exact Sciences to Offer End-to-End Cancer Testing 5.11 Guardant Health Turns to Tumor Tissue Sequencing 5.12 Tempus Inks Oncology Testing Collaboration With Bayer 5.13 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform 5.14 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test 5.15 Metastatic Cancer Markers Identified in Clinical WGS Study 5.16 Stitch Bio Bets on CRISPR Tech 5.17 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program 5.18 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx 5.19 Progress, Challenges in Liquid Biopsy Reimbursement 5.20 Israeli Startup Curesponse Raises $6M 5.21 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings 5.22 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution 5.23 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program 5.24 Germline Results Guides Precision Therapy in Advanced Cancer 5.25 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics 5.26 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers 5.27 Labs Reporting Cancer Risk Mutations from Tumor Testing 5.28 Users Begin Integrating Genomics Data for Clinical Decision Support 5.29 Fujitsu Improves Efficiency in Cancer Genomic Medicine 5.30 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results 5.31 Universal Genetic Testing for All Breast Cancer Patients 5.32 Exact Sciences buys Genomic Health 5.33 Multi-Gene Liquid Biopsy Breast Cancer Panel 5.34 Thrive to Develop Earlier Detection of Multiple Cancer Types 5.35 New Gene Panel Identifies High Risk Prostate Cancer 5.36 Guardant Health Liquid Biopsy Test to be Covered by EviCore 5.37 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services 5.38 Natera Commercializes Tumor Whole Exome Sequencing from Plasma 5.39 Inivata Completes £39.8M Series B Funding Round 5.40 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance 5.41 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials 5.42 Biodesix Acquires Integrated Diagnostics 5.43 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx 6 Profiles of Key Players 6.1 10x Genomics, Inc 7.1 Global Market Overview by Country 7.2 Global Market by Cancer Type - Overview 7.3 Global Market by Application - Overview 7.4 Global Market by Tissue - Overview 7.5 Global Market Germline & Somatic - Overview 8 Global Cancer Gene Panels & Profiles Markets - By Type of Cancer 8.1 Comprehensive Panels & Profiles 8.1.2 Chart - Comprehensive Testing Growth 8.2 Breast Cancer Gene Testing 8.2.1 Table Breast Cancer Gene Testing - by Country 8.2.2 Chart - Breast Cancer Testing Growth 8.3 Colorectal Cancer Gene Testing 8.3.1 Table Colorectal Cancer Gene Testing - by Country 8.3.2 Chart - Colorectal Cancer Gene Testing Growth 8.4 Gynecological Cancer Gene Testing 8.4.1 Table Gynecological Cancer Gene Testing - by Country 8.4.2 Chart - Gynecological Cancer Gene Testing Growth 8.5 Blood Cancer Gene Testing 8.5.1 Table Blood Cancer Gene Testing - by Country 8.5.2 Chart - Blood Cancer Gene Testing Growth 8.6 Prostate Cancer Gene Testing 8.6.1 Table Prostate Cancer Gene Testing - by Country 8.6.2 Chart - Prostate Cancer Testing Growth 8.7 Lung Cancer Gene Testing 8.7.1 Table Lung Cancer Gene Testing - by Country 8.7.2 Chart - Lung Cancer Gene Testing Growth 8.8 Other Cancer Gene Testing 8.8.1 Table Other Cancer Gene Testing - by Country 8.8.2 Chart - Other Cancer Gene Testing Growth 9 Global Cancer Gene Panels & Profiles Markets - By Type of Application 9.1 Clinical Testing 9.1.2 Chart - Clinical Testing Growth 9.2 Pharmaceutical Testing 9.2.2 Chart - Pharmaceutical Testing Growth 9.3 Research Testing 9.3.2 Chart - Research Testing Growth 10 Global Cancer Gene Panels & Profiles Markets - By Tissue Type 10.1 Solid Tissue 10.1.2 Chart - Solid Tissue Testing Growth 10.2 Liquid Tissue Testing 10.2.2 Chart - Liquid Tissue Testing Growth 11 Global Cancer Gene Testing Markets - Germline and Somatic 11.1 Global Market Somatic 11.1.2 Chart - Somatic Testing Growth 11.2 Global Market Germline 11.2.2 Chart - Germline Testing Growth 12 Potential Market Opportunity Sizes 12.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal 12.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer 12.3 Potential Market Size - Cancer Diagnosis 12.4 Potential Market Size - Therapy Selection 13 Appendices Media Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BIOARRAY Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BIOARRAY Genetics is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

M

Medical Devices

7,872 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,392 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

BIOARRAY Genetics Patents

BIOARRAY Genetics has filed 2 patents.

The 3 most popular patent topics include:

  • Breast
  • Breast cancer
  • Human proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/19/2010

9/26/2017

Breast cancer, Experimental cancer drugs, Breast, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/19/2010

00/00/0000

Grant Date

9/26/2017

00/00/0000

Title

Subscribe to see more

Related Topics

Breast cancer, Experimental cancer drugs, Breast, Clusters of differentiation

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.